Cargando…

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor

Detalles Bibliográficos
Autores principales:	Starzyk, Tory, Olsen, Rebecca, Baltazar, David, Sledge, Bridget, Mengesha, Yebabe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649578/ https://www.ncbi.nlm.nih.gov/pubmed/34926749 http://dx.doi.org/10.1016/j.jdcr.2021.10.033

Ejemplares similares

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
por: Brana, Irene, et al.
Publicado: (2012)

Mucocutaneous Adverse Reactions of Cancer Chemotherapy and Chemoradiation
por: Naveed, Sheikh, et al.
Publicado: (2019)

Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia
por: Goncalves, Marcus D., et al.
Publicado: (2022)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Treatment Strategies for Mucocutaneous Leishmaniasis
por: Palumbo, Emilio
Publicado: (2010)

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
por: Zhao, Wennan, et al.
Publicado: (2017)

Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
por: Šála, Michal, et al.
Publicado: (2016)

Tinea InVersicolor: A Rare Distribution of a Common Eruption
por: Ferry, Matthew, et al.
Publicado: (2020)

Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
por: Fang, Xiaosheng, et al.
Publicado: (2013)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Development of selective inhibitors of phosphatidylinositol 3-kinase C2α
por: Lo, Wen-Ting, et al.
Publicado: (2022)

Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses
por: Ondet, Thomas, et al.
Publicado: (2021)

The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication
por: Delang, Leen, et al.
Publicado: (2012)

Efficacy of Phosphatidylinositol-3 Kinase Inhibitors in a Primary Mouse Model of Undifferentiated Pleomorphic Sarcoma
por: Kim, Suzy, et al.
Publicado: (2012)

Phosphatidylinositol Kinases and Phosphatases in Entamoeba histolytica
por: Nakada-Tsukui, Kumiko, et al.
Publicado: (2019)

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway
por: Crowder, Robert J, et al.
Publicado: (2005)

Phosphatidylinositol-4-Phosphate 5-Kinases and Phosphatidylinositol 4,5-Bisphosphate Synthesis in the Brain
por: Volpicelli-Daley, Laura A., et al.
Publicado: (2010)

Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review
por: TRAGER, Megan H., et al.
Publicado: (2020)

Inhibitors of Phosphatidylinositol 3′-Kinases Promote Mitotic Cell Death in HeLa Cells
por: Hou, Heli, et al.
Publicado: (2012)

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection
por: Nelson, Elizabeth A., et al.
Publicado: (2017)

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
por: Shaker, Mohamed E., et al.
Publicado: (2023)

Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review
por: Gao, Yue, et al.
Publicado: (2023)

Mucocutaneous Lesions of Behçet's Disease
por: Alpsoy, Erkan, et al.
Publicado: (2007)

MUCOCUTANEOUS MANIFESTATIONS OF CHIKUNGUNYA FEVER
por: Bandyopadhyay, Debabrata, et al.
Publicado: (2010)

MUCOCUTANEOUS MANIFESTATIONS OF DENGUE FEVER
por: Thomas, Emy Abi, et al.
Publicado: (2010)

Nosocomial Dengue by Mucocutaneous Transmission
por: Chen, Lin H., et al.
Publicado: (2005)

Mucocutaneous manifestations of Cowden's syndrome
por: Reddy, Kundoor Vinay Kumar, et al.
Publicado: (2016)

Mucocutaneous Manifestations of Behçet's Disease
por: Nakamura, Koichiro, et al.
Publicado: (2021)

Mucocutaneous Adverse Reactions to COVID-19 Vaccines: Do Excipients Play a Role?
por: BIANCHI, Leonardo, et al.
Publicado: (2022)

New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus
por: Pasin, Victor Pavan, et al.
Publicado: (2015)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells
por: Baba, Atsushi, et al.
Publicado: (2013)

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
por: Shaker, Mohamed E., et al.
Publicado: (2023)

CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells
Publicado: (1995)

Successful treatment with photodynamic therapy in a patient with nasal mucocutaneous leishmaniasis undergoing treatment with TNFα inhibitor
por: Cerro, Paulina A., et al.
Publicado: (2021)

The clinical and pathologic spectrum of mucocutaneous reactions after COVID-19 vaccinations in three tertiary referral centers of northern Italy
por: Paolino, Giovanni, et al.
Publicado: (2023)

Phosphatidylinositol 3 kinase modulation of trophoblast cell differentiation
por: Kent, Lindsey N, et al.
Publicado: (2010)

Targeting Plasmodium phosphatidylinositol 4-kinase to eliminate malaria
por: McNamara, Case W, et al.
Publicado: (2013)

Architecture and dynamics of the autophagic phosphatidylinositol 3-kinase complex
por: Baskaran, Sulochanadevi, et al.
Publicado: (2014)

Exploring phosphatidylinositol 5-phosphate 4-kinase function
por: Bulley, Simon J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pdsee4kf2a165u79ijlpc0o3fv